Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
|Articles|April 2, 2012
- Pharmaceutical Technology-04-02-2012
- Volume 36
- Issue 4
Pharmaceutical Technology, April 2012 Issue (PDF)
Navigating the Equipment and Machinery Market
Advertisement
Articles in this issue
over 14 years ago
Navigating the Equipment and Machinery Marketover 14 years ago
Evaluating Impurities in Drugs (Part III of III)over 14 years ago
Scale-up Challenges in Hot-Melt Extrusionover 14 years ago
In the Spotlight April 2012over 14 years ago
A Look at INTERPHEX 2012over 14 years ago
A Sustainable Biotech Pathover 14 years ago
Ways to Recover Lost Marginsover 14 years ago
Managing Product Supply Risksover 14 years ago
Scoping out INTERPHEXAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement